Redefining Healthcare through AI-enhanced mammography Interpretation

Artificial Intelligence for early breast cancer detection


Early detection of breast cancer is important for better outcomes and treatment options. SecondReadAI™ uses artificial intelligence (AI) to perform a detailed analysis of your mammogram and alert the interpreting physician of any suspicious areas that may be too small for the human eye to identify.

 

See the  SecondReadAI™ difference

Overlooked

Abnormality Score: 84

Left image: Radiologist review: no cancer detected.

Right image:  SecondReadAI™ review: suspicion of breast cancer detected (indicated by yellow highlighted area).


How it works

Leveraging the power of AI (Artificial Intelligence), SecondReadAI™, a computer-based artificial intelligence tool, reviews and analyzes your breasts in a way that a human cannot. It looks at the images pixel by pixel and can detect suspicious breast tissue that might be obscured by dense tissue or that is too small for the human eye to detect. It is proven in clinical studies to help radiologists increase early-stage cancer detection by as much as 15%* and confidently reduce the number of unnecessary callbacks.

  • 40% of breast cancer patients can be diagnosed earlier.**

  • The five-year survival rate of cancer detected early (Stage 1,2) is 96%***

Think of it as a second set of eyes using the best medical technology to provide a more detailed analysis of your mammogram. You will have peace of mind that every detail is analyzed.

Take care of yourself

Consider  SecondReadAI™ as a second set of eyes to review the tiniest details of your mammogram and provide you with the peace of mind you deserve.

Catching potential problems early is key to staying healthy and staying ahead of breast cancer. Give this gift to yourself…because YOU’RE WORTH IT. 

View the benefits of SecondReadAI™

Expert Insights on SecondReadAI™

How SecondReadAI™ is Used

SecondReadAI™ + Radiologist

The SecondReadAI™ Experience

Is SecondReadAI™ Right for You?

SecondReadAI™ & Breast Density

Early Detection with SecondReadAI™

 

SecondReadAI™ is available at the following Rezolut centers:

 

secondreadai FAQs

  • According to the American Cancer Society, 1 in 8 women will be diagnosed with breast cancer in their lifetime. ****** The 5-year survival rate of early detected cancer (Stage 1 or 2) is 96% compared to 65% when detected in later-stage cancer (Stage 3 or 4).

    SecondReadAI™ uses Lunit INSIGHT, an artificial intelligence tool that provides a digital analysis of your mammogram and alerts the physician to suspicious areas

    According to a clinical study, Radiologists using AI (Lunit INSIGHT) significantly increased their cancer detection rate compared to the radiologists unassisted by AI.***

    In the same clinical study, Lunit INSIGHT, as a standalone product, outperformed Radiologists in detecting early-stage (T1 and node-negative) cancers by as much as 15%.**

    ***Clinical study reference https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30003-0/fulltext

    ****** https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html#:~:text=Overall%2C%20the%20average%20risk%20of,will%20never%20have%20the%20disease.

  • Your AI results are interpreted by the radiologist and are included in the mammography report.

  • No additional time is required of the patient. The AI analysis is applied after the images have been sent to the radiologist. The processing time is about 90 seconds for each study.

  • No. SecondReadAI™ exists to assist the radiologist by providing a detailed analysis of the mammogram to point out areas of concern, which the radiologist then factors into the interpretation of the exam.

  • We selected Lunit INSIGHT because it has proven high performance compared to other AI tools. In a recent publication comparing the performance of other AI tools, Lunit INSIGHT showed the best overall performance (Link to full publication in Jama Oncology)

    This AI software cannot guarantee breast cancer detection with 100% accuracy.

  • Yes. Lunit INSIGHT is FDA cleared (510K)^ product and available for clinical use in the US.

    ^A 510 (k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device (section 513 (i) (1) (A) FD&C Act).

    This AI software cannot guarantee breast cancer detection with 100% accuracy.

  • Lunit INSIGHT is widely used globally and is considered to be an accurate AI for mammography screening second look technology. It is currently used in some of the world’s largest breast screening settings to assist radiologists in early-stage cancer detection.

    This AI software cannot guarantee breast cancer detection with 100% accuracy.

  • As with most new healthcare innovations,  SecondReadAI™ is not covered by insurance, but we are offering the service at a discounted rate of $40.

    Health reimbursement accounts such as HSAs and FHAs can be used a payment options.

This AI software cannot guarantee breast cancer detection with 100% accuracy.

SecondReadAI™ is a trademark of Lunit Inc.